Le Goff G, Damiens D, Ruttee A, Jean F, Payet L, Lebon C
Infect Dis Poverty. 2024; 13(1):78.
PMID: 39456106
PMC: 11515404.
DOI: 10.1186/s40249-024-01250-z.
Douchet L, Haramboure M, Baldet T, LAmbert G, Damiens D, Gouagna L
Sci Rep. 2021; 11(1):7354.
PMID: 33795801
PMC: 8016901.
DOI: 10.1038/s41598-021-86798-8.
Eilersen A, Jensen M, Sneppen K
Sci Rep. 2020; 10(1):3907.
PMID: 32127626
PMC: 7054530.
DOI: 10.1038/s41598-020-60945-z.
Lebon C, Soupapoule K, Wilkinson D, Le Goff G, Damiens D, Gouagna L
PLoS One. 2018; 13(8):e0202236.
PMID: 30107004
PMC: 6091941.
DOI: 10.1371/journal.pone.0202236.
Manica M, Rosa R, Della Torre A, Caputo B
PeerJ. 2017; 5:e2998.
PMID: 28321362
PMC: 5357344.
DOI: 10.7717/peerj.2998.
Cross-Mating Compatibility and Competitiveness among Aedes albopictus Strains from Distinct Geographic Origins - Implications for Future Application of SIT Programs in the South West Indian Ocean Islands.
Damiens D, Lebon C, Wilkinson D, Dijoux-Millet D, Le Goff G, Bheecarry A
PLoS One. 2016; 11(11):e0163788.
PMID: 27806056
PMC: 5091895.
DOI: 10.1371/journal.pone.0163788.
Imported Chikungunya fever case in Greece in June 2014 and public health response.
Tsiodras S, Pervanidou D, Papadopoulou E, Kavatha D, Baka A, Koliopoulos G
Pathog Glob Health. 2016; 110(2):68-73.
PMID: 27159571
PMC: 4894267.
DOI: 10.1080/20477724.2016.1176311.
Viremia in North American Mammals and Birds After Experimental Infection with Chikungunya Viruses.
Bosco-Lauth A, Nemeth N, Kohler D, Bowen R
Am J Trop Med Hyg. 2015; 94(3):504-6.
PMID: 26666699
PMC: 4775881.
DOI: 10.4269/ajtmh.15-0696.
Suramin Inhibits Chikungunya Virus Entry and Transmission.
Ho Y, Wang Y, Lu J, Wu T, Lin L, Kuo S
PLoS One. 2015; 10(7):e0133511.
PMID: 26208101
PMC: 4514758.
DOI: 10.1371/journal.pone.0133511.
Deliberate attenuation of chikungunya virus by adaptation to heparan sulfate-dependent infectivity: a model for rational arboviral vaccine design.
Gardner C, Hritz J, Sun C, Vanlandingham D, Song T, Ghedin E
PLoS Negl Trop Dis. 2014; 8(2):e2719.
PMID: 24587470
PMC: 3930508.
DOI: 10.1371/journal.pntd.0002719.
Review of insecticide resistance and behavioral avoidance of vectors of human diseases in Thailand.
Chareonviriyaphap T, Bangs M, Suwonkerd W, Kongmee M, Corbel V, Ngoen-Klan R
Parasit Vectors. 2013; 6:280.
PMID: 24294938
PMC: 3850650.
DOI: 10.1186/1756-3305-6-280.
Dried-blood spots: a cost-effective field method for the detection of Chikungunya virus circulation in remote areas.
Andriamandimby S, Heraud J, Randrianasolo L, Rafisandratantsoa J, Andriamamonjy S, Richard V
PLoS Negl Trop Dis. 2013; 7(7):e2339.
PMID: 23936570
PMC: 3723542.
DOI: 10.1371/journal.pntd.0002339.
Nonstructural protein 2 (nsP2) of Chikungunya virus (CHIKV) enhances protective immunity mediated by a CHIKV envelope protein expressing DNA Vaccine.
Bao H, Ramanathan A, Kawalakar O, Sundaram S, Tingey C, Bian C
Viral Immunol. 2013; 26(1):75-83.
PMID: 23409931
PMC: 4845693.
DOI: 10.1089/vim.2012.0061.
North American wetlands and mosquito control.
Rey J, Walton W, Wolfe R, Connelly C, OConnell S, Berg J
Int J Environ Res Public Health. 2012; 9(12):4537-605.
PMID: 23222252
PMC: 3546777.
DOI: 10.3390/ijerph9124537.
Poly (I:C), an agonist of toll-like receptor-3, inhibits replication of the Chikungunya virus in BEAS-2B cells.
Li Y, Siripanyaphinyo U, Tumkosit U, Noranate N, A-Nuegoonpipat A, Pan Y
Virol J. 2012; 9:114.
PMID: 22698190
PMC: 3490739.
DOI: 10.1186/1743-422X-9-114.
Epidemiology, clinical manifestations, and long-term outcomes of a major outbreak of chikungunya in a hamlet in sri lanka, in 2007: a longitudinal cohort study.
Kularatne S, Weerasinghe S, Gihan C, Wickramasinghe S, Dharmarathne S, Abeyrathna A
J Trop Med. 2012; 2012:639178.
PMID: 22496701
PMC: 3306924.
DOI: 10.1155/2012/639178.
Biogeography of the two major arbovirus mosquito vectors, Aedes aegypti and Aedes albopictus (Diptera, Culicidae), in Madagascar.
Nantenaina Raharimalala F, Ravaomanarivo L, Ravelonandro P, Rafarasoa L, Zouache K, Tran-Van V
Parasit Vectors. 2012; 5:56.
PMID: 22433186
PMC: 3359177.
DOI: 10.1186/1756-3305-5-56.
Early appearance of neutralizing immunoglobulin G3 antibodies is associated with chikungunya virus clearance and long-term clinical protection.
Kam Y, Simarmata D, Chow A, Her Z, Teng T, Ong E
J Infect Dis. 2012; 205(7):1147-54.
PMID: 22389226
PMC: 3295607.
DOI: 10.1093/infdis/jis033.
Early neutralizing IgG response to Chikungunya virus in infected patients targets a dominant linear epitope on the E2 glycoprotein.
Kam Y, Lum F, Teo T, Lee W, Simarmata D, Harjanto S
EMBO Mol Med. 2012; 4(4):330-43.
PMID: 22389221
PMC: 3376860.
DOI: 10.1002/emmm.201200213.
A DNA vaccine against chikungunya virus is protective in mice and induces neutralizing antibodies in mice and nonhuman primates.
Mallilankaraman K, Shedlock D, Bao H, Kawalekar O, Fagone P, Ramanathan A
PLoS Negl Trop Dis. 2011; 5(1):e928.
PMID: 21264351
PMC: 3019110.
DOI: 10.1371/journal.pntd.0000928.
